A Bayesian approach to jointly estimate centre and treatment by centre heterogeneity in a proportional hazards model

被引:26
作者
Legrand, C
Ducrocq, V
Janssen, P
Sylvester, R
Duchateau, L
机构
[1] European Inst Res & Treatment Canc, B-1200 Brussels, Belgium
[2] INRA, Genet Quantitat & Appl Stn, Jouy En Josas, France
[3] Hasselt Univ, Ctr Stat, B-3590 Diepenbeek, Belgium
[4] Univ Ghent, Fac Vet Med, Dept Physiol Biochem & Biometr, B-9000 Ghent, Belgium
关键词
frailty model; proportional hazards; random treatment by centre interaction; Bayesian inference; Laplace integration; bladder cancer;
D O I
10.1002/sim.2475
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
When multicentre clinical trial data are analysed, it has become more and more popular to look for possible heterogeneity in outcome between centres. However, beyond the investigation of such heterogeneity, it is also interesting to consider heterogeneity in treatment effect over centres. For time-to-event outcomes, this may be investigated by including a random centre effect and a random treatment by centre interaction in a Cox proportional hazards model. Assuming independence between the random effects, we propose a Bayesian approach to fit our proposed model. The parameters of interest are the variance components sigma(2)(0) and a; of these random effects, which can be interpreted as a measure of centre and treatment effect over centres heterogeneity of the hazard. These variance components are estimated from their marginal posterior density after integrating out the fixed treatment effect and the random effects. As this integration cannot be performed analytically, the marginal posterior density is approximated using the Laplace integration technique. Statistical inference is then based on the characteristics of the posterior marginal density, such as the mode and the standard deviation. We demonstrate the proposed technique using data from a pooled database of seven EORTC bladder cancer clinical trials. Substantial centre and treatment effect over centres heterogeneity in disease-free interval was found. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:3789 / 3804
页数:16
相关论文
共 22 条
[1]   INTRAVESICAL ADJUVANT CHEMOTHERAPY FOR SUPERFICIAL TRANSITIONAL-CELL BLADDER-CARCINOMA - RESULTS OF 2 EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER RANDOMIZED TRIALS WITH MITOMYCIN-C AND DOXORUBICIN COMPARING EARLY VERSUS DELAYED INSTILLATIONS AND SHORT-TERM VERSUS LONG-TERM TREATMENT [J].
BOUFFIOUX, C ;
KURTH, KH ;
BONO, A ;
OOSTERLINCK, W ;
KRUGER, CB ;
DEPAUW, M ;
SYLVESTER, R ;
DENIS, L ;
NEWLING, D ;
HALL, R ;
BRESSEL, M ;
CASSELMAN, J ;
SMITH, P ;
ROBINSON, M ;
KEUPPENS, F ;
TOLLEY, D ;
JAKSE, G ;
BOLLACK, C ;
VERGISON, B ;
HOEKSTRA, W ;
DASILVA, FC ;
GROEN, J ;
RICHARDS, B ;
PAVONEMACALUSO, M ;
VANDERMEIJDEN, A ;
ZWARTENDIJK, H ;
JACOBI, G ;
VANCAUBERG, R ;
SCHRODER, F ;
HIRDES, D ;
LEISINGER, H ;
RIEDL, H ;
LUDWIG, P ;
ROOZENDAAL, K ;
MARECHAL, L ;
VANAUBEL, O ;
CONSIDINE, J ;
DEBRUYNE, F ;
CARREIRA, F ;
DEWALL, D ;
MENSINK, H ;
VIGGIANO, G .
JOURNAL OF UROLOGY, 1995, 153 (03) :934-941
[2]   ADJUVANT CHEMOTHERAPY OF RECURRENT SUPERFICIAL TRANSITIONAL CELL-CARCINOMA - RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER RANDOMIZED TRIAL COMPARING INTRAVESICAL INSTILLATION OF THIOTEPA, DOXORUBICIN AND CISPLATIN [J].
BOUFFIOUX, C ;
DENIS, L ;
OOSTERLINCK, W ;
VIGGIANO, G ;
VERGISON, B ;
KEUPPENS, F ;
DEPAUW, M ;
SYLVESTER, R ;
CHEUVART, B .
JOURNAL OF UROLOGY, 1992, 148 (02) :297-301
[3]   Understanding heterogeneity in generalized mixed and frailty models [J].
Duchateau, L ;
Janssen, P .
AMERICAN STATISTICIAN, 2005, 59 (02) :143-146
[4]   The shared frailty model and the power for heterogeneity tests in multicenter trials [J].
Duchateau, L ;
Janssen, P ;
Lindsey, P ;
Legrand, C ;
Nguti, R ;
Sylvester, R .
COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2002, 40 (03) :603-620
[5]  
DUCROCQ V, 1994, 5 WORLD C GEN APPL L, V22, P51
[6]  
DUCROCQ V, 1996, GENET SEL EVOL, V28, P509
[7]  
Ducrocq V., 1998, 6 WORLD C GEN APPL L, P447
[8]  
Gamerman D., 1997, MARKOV CHAIN MONTE C
[9]  
Ibrahim J.G., 2001, BAYESIAN SURVIVAL AN, DOI DOI 10.1007/978-1-4757-3447-8
[10]   ADJUVANT CHEMOTHERAPY OF SUPERFICIAL TRANSITIONAL CELL BLADDER-CARCINOMA - PRELIMINARY-RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER RANDOMIZED TRIAL COMPARING DOXORUBICIN HYDROCHLORIDE, ETHOGLUCID AND TRANS-URETHRAL RESECTION ALONE-R [J].
KURTH, KH ;
SCHRODER, FH ;
TUNN, U ;
AY, R ;
PAVONEMACALUSO, M ;
DEBRUYNE, F ;
DEPAUW, M ;
DALESIO, O ;
TENKATE, F .
JOURNAL OF UROLOGY, 1984, 132 (02) :258-262